Therapy Areas: Diabetes
BioCity's SC0062 receives Chinese Breakthrough Therapy Designation for diabetic kidney disease with albuminuria
26 June 2025 - Chinese biopharmaceutical company BioCity Biopharma announced on Wednesday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has ...
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
25 June 2025 - Innovent Biologics Inc (HKEX: 01801), a China-based biopharmaceutical company that develops, manufactures and commercialises medicines for the treatment of oncology, autoimmune, cardiov...
BrightGene presents BGM0504 positive Phase 2 data for weight management and type 2 diabetes
24 June 2025 - Chinese pharmaceutical company BrightGene Pharmaceutical Co Ltd announced on Tuesday that it has presented data from two Phase 2 studies for BGM0504, its investigational dual agonist ta...
Amgen reports results of Phase 2 MariTide obesity study
24 June 2025 - US pharmaceutical company Amgen (NASDAQ:AMGN) on Monday reported full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, pe...
European Medicines Agency recommends approval of Alvotech's biosimilar to Eylea
23 June 2025 - Biotechnology company Alvotech SA (NASDAQ:ALVO) announced on Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinio...
Gan & Lee presents trial results for novel diabetes therapies at ADA's 85th Scientific Sessions
23 June 2025 - Chinese pharmaceutical company Gan & Lee Pharmaceuticals (SH:603087) announced on Saturday that it presented multiple Phase 2 clinical study results of ultra-long-acting GLP-1 recep...